



Biomax News • Biomax News • Biomax News •

*FOR IMMEDIATE RELEASE*

Contact:

Peyton Hughes  
Biomax Informatics AG  
Lochhamer Str. 11  
82152 Martinsried  
D-Germany  
Tel: +49 89 895574-0  
Fax: +49 89 895574-25  
Internet site: [www.biomax.de](http://www.biomax.de)

**BIOMAX INFORMATICS AG  
Launches Version 4.0 of the BioRS™ Integration and Retrieval System**

**MARTINSRIED, Germany** – April 25, 2001 – Biomax Informatics AG announces a new version of the BioRS™ Integration and Retrieval System, which enables researchers instant access to multiple biological data sources, including in-house proprietary databases. Although the BioRS system has always been able to integrate flat-file and relational databases, both internally represented in eXtensible Markup Language (XML) format, the new release further enhances performance and keeps the BioRS system at the cutting edge of innovative information exchange technology. The new developments are part of the company's ongoing commitment to providing the most universal and user-friendly bioinformatics systems available.

The BioRS system, first launched in 1998, is a high-speed, sophisticated search and retrieval system for biological information, such as DNA sequences. The speed and flexibility of the BioRS system greatly facilitates gene discovery projects, including genomics, proteomics and drug targeting and delivery. The system enables researchers to quickly and efficiently retrieve all known biological data on a given topic, independent of the size of the database or the complexity of the query. BioRS uses convenient web interfaces and standardizes data formats from different databases using XML for quick, easy access to data, independent of the source format. Both flat-file and relational databases, including proprietary databases, are easily integrated.

The new release of the BioRS system further facilitates the use of relational databases. With BioRS version 4.0, the format of an existing relational database can be copied making the creation and integration of new relational databases as easy as possible.

Additionally, the new release will allow users to execute searches using phrases with all indexed fields, refining queries for more relevant search results.

In response to customer requests, the query archive has been enhanced so that queries created by an individual user may be accessed by other users. This new feature allows information to be shared more efficiently by reducing redundant searches and ensuring that research goals are reached even more quickly.

“Since our goal for the BioRS system has always been to make it the most efficient and effective database search and integration system, regardless of the type of databases used, we are pleased to bring these innovative features and their corresponding benefits to new and current customers,” said Dr. Klaus Heumann, CEO of Biomax. “As a provider of customized bioinformatics solutions, Biomax is in constant contact with customers and we make it our goal to constantly upgrade and fit our software to the requirements and demands of the user.”

In January 2001, Biomax granted InforMax of Rockville, Maryland exclusive, worldwide distribution rights to the BioRS Integration and Retrieval System. “InforMax has 500 customer organizations in Europe, including more than 150 in Germany alone,” said Heumann. “Integrating the BioRS system with InforMax’s High-Throughput Research<sup>®</sup> solution set will leverage our combined strength in Germany and create global synergies for both companies. We are excited to be working with InforMax to deliver this industry-leading bioinformatics solution to the market and are confident that this alliance will significantly increase market share for BioRS worldwide.”

## About Biomax

Biomax Informatics AG (Martinsried, Germany), a leader in the development of customized bioinformatics solutions, was founded in 1997 as a spin-off of the GFS-MIPS academic research group of the German Research Center for Environment and Health (Neuherberg) and the Munich Information Center for Protein Sequences (Max Planck Institute for Biochemistry, Martinsried). Founded by Dr. D. Frishman, Dr. K. Heumann and Prof. Dr. H. W. Mewes, Biomax developed the well-known Pedant-Pro<sup>™</sup> Sequence Analysis Suite, the BioRS Integration and Retrieval System, and other bioinformatics tools used in metabolic pathway, proteomics, and gene expression analyses. Additional information about Biomax can be found at the company's site on the World Wide Web at [www.biomax.de](http://www.biomax.de).

## About InforMax

InforMax is a leading global developer of bioinformatics software for High-Throughput Research. InforMax® products are used by more than 1650 research organizations and more than 22,000 individual scientists worldwide (as of December 31, 2000) to understand and extract value from the massive amounts of data being generated by the genomic revolution. Among the Company's customers are 22 of the top 25 pharmaceutical companies. InforMax was founded in 1990 by Alex Titomirov, Ph.D. Its mission is to speed the pace of medical progress by enabling High-Throughput Research, a process for compressing the time it takes to discover and validate the biological targets most likely to result in breakthrough therapeutics, diagnostics or biomolecular interventions to cure or prevent disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI® Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax™ for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the company's web site at <http://www.informaxinc.com> .

*Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks associated with the InforMax's technologies and the need to keep pace with rapid technological change, the Company's dependence for future revenues on its ability to increase sales of its enterprise platform and successfully establish the GenoMax brand, the Company's dependence on developing and maintaining strategic alliances, development and availability of competitive products or technologies, the possibility that the Company may not achieve or maintain profitability in the future, the likelihood that the Company's results may fluctuate from quarter to quarter, dependence on patents and the ability to defend the Company's intellectual property rights. These factors and others are more fully described in the Company's Registration Statement on Form S-1, as filed with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook only as of the date given.*

**InforMax, the InforMax logo, and Vector NTI are registered trademarks and GenoMax and High-Throughput Research are trademarks of InforMax, Inc.**

**Biomax, BioRS and Pedant-Pro are trademarks of Biomax Informatics AG.**

**All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners.**

**###**